BioWorld: Selection waits on efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis
By Cormac Sheridan, Staff Writer – Published by BioWorld™ – The coming months represent a crucial phase in the development of Selection Inc., a U.S.-German firm that is tackling a target in autoimmune disease that has evaded the best efforts…
Read More